6 hasil untuk "Muhammad Shaalan Beg"
Menampilkan 1–6 · 0,70 detik · RSS
-
Artikel Jurnal
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial. Objective: To determine 2-year…
-
Artikel Jurnal
Surgical Outcome Results From SWOG S1505
OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel…
-
Artikel Jurnal Teks lengkap
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours…
-
Artikel Jurnal Teks lengkap
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI…